1062-44 Hypothermia, but not N-acetylcysteine or fenoldopam, prevents experimental contrast-induced nephropathy  by Dae, Michael W et al.
48A ABSTRACTS - Angiography & Interventional Cardiology JACC March 3, 2004
An
gi
og
ra
ph
y 
&
 In
te
rv
en
tio
na
l C
ar
di
ol
og
y
Conclusions: CrCl reduction after PCI is infrequent in patients with normal baseline
renal function. A modest decrease in CrCl, even after adjusting for other variables, is
associated with significant increases in mortality, bleeding complications and a longer
length of hospitalization. The association with intra-aortic balloon pump use suggests an
embolic mechanism which warrants further investigation.
1062-43 Preprocedure Hyperglycemia Is Stongly Assoicated 
With Restenosis After Coronary Intervention in 
Diabetics
Arvind K. Sharma, Joseph Lindsay, Daniel A. Canos, Ellen Pinnow, Sue Apple, Giacomo 
Ruotolo, Mohan Nandalur, Mevan Wijetunga, Howard Cooper, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background:Restenosis rate after percutaneous coronary intervention (PCI) in diabetic
pts is at least twice that of nondiabetics. We explored potential relationships between res-
tenosis and metabolic factors in diabetics. Methods:Fasting blood samples were
obtained from 162 diabetics (98 men, mean age 62.8±10.7) immediately prior to PCI and
analyzed for insulin, glucose, and hemoglobin A1c (A1c). Insulin resistance (IR) was cal-
culated from the HOMA formula. All pts had successful PCI. Baseline clinical, procedural
and follow-up information was recorded. The primary end point was target vessel revas-
cularization (TVR) rate by 9 months. Results:The insulin level was increased in virtually
all pts(mean 21.0±15.2 µU/ml). No association between TVR and insulin levels or calcu-
lated IR was identified. Only blood glucose level was significantly associated with TVR
(p<0.035).This effect was independent of A1c levels (Figure).The 9-month death plus
nonfatal infarction rate was low (4.2%). No association with the independent variables
could be shown. Conclusion:These data do not support a role for either fasting insulin
level or calculated IR in restenosis. Glucose levels >135 mg/dl were associated with high
TVR rates regardless of A1c levels. The metabolic milieu at the time of the PCI may influ-
ence restenosis.
1062-44 Hypothermia, but Not N-Acetylcysteine or Fenoldopam, 
Prevents Experimental Contrast-Induced Nephropathy
Michael W. Dae, Dong W. Gao, Carol A. Stillson, Gregg W. Stone, Philip C. Ursell, 
University of California at San Francisco, San Francisco, CA, Cardiovascular Research 
Foundation, New York, NY
Background: Contrast-induced nephropathy (CIN) is common after angiographic proce-
dures in high-risk patients. Other than hydration, there is no effective treatment to prevent
CIN. We tested the hypothesis that hypothermia would protect the kidneys from CIN.
Methods: We studied a total of 29 rabbits: controls 39°C, pretreatment with N-Acetylcys-
teine 39°C (NAC, 120 mg/kg over 1 hour, then 11 mg/kg/hr x 4 hours), Fenoldopam 39°C
(0.05 µg/kg/hr x 4 hours), and hypothermia (32°C; 35°C). Hypothermia was induced
using an esophageal heat exchange catheter (Radiant Medical, Inc). Core temperature
was measured in the descending aorta. Rabbits were cooled to target temperature prior
to contrast injection, maintained for 3 hours, then rewarmed. NAC was infused starting 2
hours before contrast injection (Fenoldopam 1 hr before). Iopromide (Ultravist,10.0 g I/kg)
was injected via femoral vein. Serum creatinine (Cr, mg/dl) was measured at baseline,
24, and 48 hours post injection. Kidneys were removed at 48 hours for histology.
Results: Cr results are shown in the table. Significant increases in Cr and extensive
tubular necrosis occurred in controls, NAC, and Fenoldopam, but not in the hypothermic
animals.
Conclusions: Hypothermia started prior to contrast injection provided complete protec-
tion of the kidneys in this experimental model of CIN, and proved superior to NAC and
Fenoldopam. These results suggest that hypothermia may provide a new and effective
strategy for prevention of CIN in high-risk patients. 
1062-45 Prevention of Contrast-Agent-Induced Nephropathy in 
Patients Undergoing a Coronary Procedure by Ascorbic 
Acid
Konstantinos S. Spargias, Elias Alexopoulos, Stamatis Kyrzopoulos, Panagiotis Iakovis, 
Athanassios Manginas, Vassilios Voudris, Gregory Pavlides, Demetrios Kremastinos, 
Dennis V. Cokkinos, Onassis Heart Centre, Athens, Greece
Background: Contrast agents can cause a reduction in renal function that may be due to
generation of reactive oxygen species. There is some evidence suggesting that the
administration of the antioxidant acetylcysteine prevents this renal impairment. The
action of other antioxidant agents, such as ascorbic acid, has not been investigated.
Methods: We conducted a randomized, double-blind, placebo-controlled, prospective
study of ascorbic acid in 231 patients who underwent coronary angiography or interven-
tion and had a serum creatinine concentration > 1.2 mg/dl. Ascorbic acid (3gr at least 2
hours before the procedure, and 2 gr in the night and the morning after the procedure) or
placebo was administered orally. An acute contrast-agent-induced reduction in renal
function was defined as an at least 0.5 mg/dl or a 25% increase in the baseline serum
creatinine concentration measured 2-5 days after the procedure.
Results: Eleven of the 118 patients (9.3%) in the ascorbic acid group, and 23 of the 113
patients (20.4%) in the placebo group achieved the study end-point (p=0.02, relative risk
0.38, 95% confidence interval 0.17 to 0.85). The mean serum creatinine concentration
increased significantly in the placebo group [1.36 (SD:0.50) to 1.50 (0.54) mg/dl,
p<0.001], but not in the ascorbic acid group [1.46 (0.52) to 1.52 (0.64) mg/dl, p=0.20].
The mean increase in the serum creatinine concentration in the placebo group was
greater than that in the ascorbic acid group [0.14 (0.30) vs. 0.06 (0.35) mg/dl, p=0.001].
Conclusion: Prophylactic oral administration of ascorbic acid may protect against con-
trast-agent-induced nephropathy in high-risk patients undergoing a coronary procedure.
1062-46 Preventive Effects of Rosiglitazone on Restenosis After 
Coronary Stent Implantation in Patients With Type 2 
Diabetes Mellitus
Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Sung-Hee Choi, Soo-Kyung Kim, Bong-
Soo Cha, Yonsei University College of Medicine, Seoul, South Korea
Background: After coronary stenting, the restenosis rate is known to be higher in DM
than non-DM patients due to excessive intimal hyperplasia. We investigated the efficacy
of rosiglitazone for preventing restenosis after coronary stenting in diabetic patients.
Methods : We conducted a prospective case-controlled trial involving 95 diabetic
patients (control n=48, rosiglitazone (4 mg per day) group n=47) undergoing coronary
stenting. Serum glucose level and cholesterol were tried to be optimized using additional
hypoglycemic agents and statins. An angiographic follow-up was performed at six
months. Results: A follow-up angiography was performed in 83 patients including 45
patients with 55 lesions in control group (m:f = 31:11, age 59.9±9.3 years), and 38
patients with 51 lesions in the rosiglitazone group (m:f=24:18, age 60.9±9.3 years). The
baseline clinical profile and blood chemistry between two groups were not different.
Baseline angiographic data of control and rosiglitazone group were as following : refer-
ence diameter 3.15±0.49 vs. 3.16±0.49 mm (p=NS), minimal lumen diameter (MLD)
0.65±0.41 vs. 0.83±0.57 mm (p=NS), diameter stenosis (DS) 79.4±12.8 % vs. 74.4±15.8
%, lesion length 16.48±5.16 vs. 19.02±6.09 mm (p<0.05). There was no difference in
MLD or acute gain after coronary stenting between the two groups. The follow-up angiog-
raphy showed a significantly lower binary restenosis rate in the rosiglitazone group than
the control group (17.6% vs. 38.2%, P = 0.03). The follow-up DS (24.2 ± 23.2% vs. 42.9
± 32.2%, P = 0.001) and loss index (0.49±0.41 vs. 0.27±0.30, p=0.008) were also lower
in the rosiglitazone group. Major adverse cardiac events occurred less frequently in the
rosiglitazone group (10.5% vs 20%, p=0.244) at 6 months, although it was not statistically
significant. The serum glucose, insulin, lipid concentrations were similar at 6- month fol-
low-up in the both groups. Conclusions: Rosiglitazone effectively reduced restenosis in
diabetic patients after coronary stenting. This effect is probably related to pleotrophic
property of rosiglitazone rather than its hypoglycemic effect.
1062-47 Marked Improvements in In-Hospital Outcomes 
Following Contemporary Percutaneous Coronary 
Intervention in Patients With Diabetes
David O. Williams, Alice K. Jacobs, Helen A. Vlachos, Katherine M. Detre, Rhode Island 
Hospital, Providence, RI
Background: Presence of diabetes mellitus (DM) has been associated with adverse
results among patients (pts) treated by percutaneous coronary intervention (PCI).
Methods: We sought to determine whether advances in PCI over time have impacted in-
hospital clinical outcomes of pts with DM. Pts with DM were identified and analyzed in the
1985-86 PTCA Registry (n=325) and in the 1997-2001 enrollment waves of the NHLBI
Dynamic Registry (n=622).
Results: Pts in the Dynamic Registry were older (64.1 vs. 60.7 years, p<0.001), more
often had history of hypertension (80.0% vs. 61.8%, p<0.001), severe concomitant non-
cardiac disease (45.5% vs. 9.5%, p<0.001), and lower LV ejection fractions (50.4% vs.
57.8%, p<0.001). No differences were observed in gender, prior CABG, history of CHF,
number of vessels diseased or mean number of lesions. AMI was more often an indica-
tion for PCI in the Dynamic Registry (27.7% vs. 7.4%, p<0.001) and procedures were
more often emergent or urgent. In the Dynamic Registry, fewer lesions were attempted
per pt (1.4 vs. 1.7, p<0.001) and lesion location was less often the LAD (36.8% vs.
45.3%, p<0.05). Stents were used in 87.5% of Dynamic Registry pts and in no 1985-86
pts. Angiographic success was higher in the Dynamic Registry (94.8% vs. 78.1%,
p<0.001) and abrupt closure (0.9% vs. 2.2%, p<0.05), death (1.9% vs. 4.3%, p<0.05), MI
(1.0% vs. 7.4%, P<0.001) and in-hospital CABG (0.8% vs. 6.2%, p<0.001) were less
common.
Conclusions: Although pts with DM having contemporary PCI were older and had more
Cr Baseline Cr 24 hrs Cr 48 hrs
Control, 39°C (n=6) 1.1±0.2 3.9±1.8* 5.8±3.3*
NAC (n=6) 0.8±0.1 2.3±0.9* 4.3±1.6*
Fenoldopam (n=6) 1.0±0.2 2.8±1.0* 5.3±1.3*
Hypo-35°C (n=5) 0.8±0.1 1.1±0.2**# 0.9±0.2#
Hypo-32°C (n=6) 1.2±0.2 1.1±0.3# 1.0±0.3#
*P<0.01 vs baseline
**P=0.05 vs baseline
#P<0.01 vs
Control,NAC,
Fenoldopam
